Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 11001 participants.

Also called NCT02406677

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose health services research
Phase
Phase 4
Enrolled
  • 11,001 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02406677
Other papers using this trial's data
  • Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill: A Secondary Analysis of the Cluster Randomized ARTEMIS Trial JAMA cardiology, 2020-05-01 DOI, PubMed 32129795, PMC7057174 Not in the PMC Open Access subset.
  • Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial JAMA cardiology, 2020-01-01 DOI, PubMed 31721978, PMC6865296 Not in the PMC Open Access subset.
  • Challenge in Predicting Persistence to P2Y12 Inhibitors: A Perspective From the ARTEMIS Trial Journal of the American Heart Association, 2023-06-20 DOI, PubMed 37301758, PMC10356056 In the PMC Open Access subset under CC BY-NC-ND.
  • Copayment Reduction Voucher Utilization and Associations With Medication Persistence and Clinical Outcomes: Findings From the ARTEMIS Trial Circulation. Cardiovascular quality and outcomes, 2020-05 DOI, PubMed 32393129
  • Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out-Of-Pocket Expenses? Insights From ARTEMIS Journal of the American Heart Association, 2022-10-18 DOI, PubMed 36250667, PMC9673662 In the PMC Open Access subset under CC BY-NC-ND.
  • Effect of Medication Co-payment Vouchers on P2Y12 Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction: The ARTEMIS Randomized Clinical Trial JAMA, 2019-01-01 DOI, PubMed 30620370, PMC6583585 Not in the PMC Open Access subset.
  • Impact of a Copayment Reduction Intervention on Medication Persistence and Cardiovascular Events in Hospitals With and Without Prior Medication Financial Assistance Programs Journal of the American Heart Association, 2020-04-21 DOI, PubMed 32299284, PMC7428537 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02406677. Randomized; no masking; primary purpose health services research. Start 2015-06-05 (actual); primary completion 2017-10-23 (actual). Results posted on 2019-10-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study
Acronym
ARTEMIS
Condition
Cost Sharing, Acute Coronary Syndrome
Intervention (Other)
Study voucher card
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Duke Clinical Research Institute (class: other)

Record details

Record id
cardio:ct-nct02406677
Content hash
a13c94116c95add4bab2d9fc9ed6aae0a9ecfcfc85e2e7cb9765aca201a0a493